Additional file 1 of Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model

Additional file 1

Multivariable linear regression analysis on the parameters affecting CDH2 and MCP-1 mRNAs level.

Multivariable linear regression analysis on the parameters affecting CDH2 and MCP-1 mRNAs level.</p

Correlations of CDH1, CDH2, MCP-1, and PAI-1 mRNAs with demographic data and clinical laboratory tests in all participants.

Correlations of CDH1, CDH2, MCP-1, and PAI-1 mRNAs with demographic data and clinical laboratory tests in all participants.</p

Demographic and clinical laboratory characteristics.

Demographic and clinical laboratory characteristics.</p

Diagnostic performance of 1/CDH2 mRNA and 1/MCP-1 mRNA for overt DN detection.

Diagnostic performance of 1/CDH2 mRNA and 1/MCP-1 mRNA for overt DN detection.</p

S1 Data -

(XLSX)</p

Diagnostic performance of 1/CDH2 mRNA and 1/MCP-1 mRNA for incipient DN detection.

Diagnostic performance of 1/CDH2 mRNA and 1/MCP-1 mRNA for incipient DN detection.</p

The receiver operating characteristic (ROC) analyses of 1/CDH2 mRNA and 1/MCP-1 mRNA to differentiate incipient DN patients from DM patients.

The receiver operating characteristic (ROC) analyses of 1/CDH2 mRNA and 1/MCP-1 mRNA to differentiate incipient DN patients from DM patients.</p

Pairwise comparisons regarding clinical laboratory tests of overt DN group, incipient DN group, DM group, and control group versus each other.

Pairwise comparisons regarding clinical laboratory tests of overt DN group, incipient DN group, DM group, and control group versus each other.</p

MCP-1 mRNA expression level in blood extracellular vesicles.

p value is calculated by the Mann–Whitney U test.</p